Results of Joint Research on Drug Development with Nanjing Medical University Published in a Leading International Journal

OCIUM Inc. (Head Office: Chuo-ku, Tokyo; President: Katsuhisa Horimoto) and the Nanjing Medical University College of Pharmacy(https://english.njmu.edu.cn/) published the results of their joint research in the European Journal of Medicinal Chemistry [IF7.3] on April 6 (https://doi.org/10. 1016/j.ejmech.2025.117597).

The study was led by Professor Dongyin Chen of the School of Pharmacy at Nanjing Medical University, and the paper reports the discovery of a promising drug candidate for Parkinson’s disease (PD) complicated by depression.

The synergistic effect of the collaboration between our drug repositioning platform and the compound synthesis and expansion technology of Nanjing Medical University has accelerated the discovery and development of drug seeds for various diseases.

About SOCIUM Inc.
SOCIUM Inc. is a venture company that discovers drug seeds, especially drug candidates for the treatment of rare diseases, by utilizing drug repositioning(*1) technology. With the vision of “providing medicine to those without it, and providing medicine to those for whom it is ineffective”, we are working to overcome the unmet medical needs of patients. For more information about our unique drug discovery approach and our progress, please refer to the relevant sections of our website (https://socium.co.jp/drug_discovery/ ; https://socium.co.jp/2024/09/17/2024091701/).

(*1) Drug repositioning
To discover new applicable indications for existing drugs on the market or drugs in development. Also, to discover existing drugs (known but new chemical structures) that show efficacy against the target disease.

About Parkinson’s disease
Parkinson’s disease is a neurodegenerative disease in which certain areas of the brain degenerate and progress, with tremors (shaking), slow movements, muscle stiffness (muscle rigidity), and postural retention problems (falling easily) as the main motor symptoms, and often occurs in people over age 50. It is also known to cause depression (https://www.parkinson.org/understanding-parkinsons/non-movement-symptoms/depression).

For inquiries regarding this matter, please contact
SOCIUM Inc.
5th, 6th, and 7th floors of Waterfront Center Annex, National Institute of Advanced Industrial Science and Technology (AIST)
2-4-7 Aomi, Koto-ku, Tokyo, Japan 1350064
https://socium.co.jp
E-mail: contact@socium.co.jp